Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights.
Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights:
- Global Nanoparticle Drug Delivery Market Opportunity > USD 300 Billion by 2028
- Nanoparticle Drug Deliver Price and Dosage Insight By Therapeutic: Cancer, Anemia, Autoimmune Diseases, Neurological Disorders
- Global Nanoparticle Drug Market Regional Analysis: US, Europe, China, Japan, India, Taiwan, South Korea, Canada
- Nanoparticle Therapeutics Approved Drugs Sales Insight: 15 Drugs
- Nanoparticle Therapeutics Approved Drugs Sales Forecast 2028: 15 Drugs
- Global Nanoparticle Drugs Clinical Pipeline Insight By Phase, Company and Indication: > 400 Drugs
- Nanoparticle Drug Delivery - Market Trend and Patent Distribution Analysis
Download Report:
https://www.kuickresearch.com/report-nanoparticle-drug-delivery-market-nanomedicine-market
Effective targeted delivery of drugs to specific organs, tissue, or cells is crucial in the pharmaceutical industry, making drug carriers as important as the drug itself. The rising demand for optimized drug delivery coupled with the advancement in the field of biotechnology has led to introduction of nanoparticle drug delivery. In medicine, nanotechnology used in drug delivery enhances the performance of therapeutic drugs, improves drug solubility, enables targeted drug delivery to specific sites in the body, minimizes side effects, and prolongs drug retention times. Till date several nanoparticle drug deliveries have been entered the market. Their encouraging response and huge clinical success have paved the way for further research and development activities in this sector.
Large number of ongoing clinical studies is utilizing novel nanoparticle material which has the ability to enhance the efficacy and overcome the limitations of already approved nanocarriers in the market. For instance, Mesoporous silica nanoparticles (MSNs) which are inorganic nanocarriers have gained considerable attention which is mainly due to their remarkable in vivo efficacy when identifying or treating a range of diseases. With the added advantage of modifiable mesoporous properties such as pore size, high drug loading, porosity and surface properties, which can be altered in preparation of MSNs, the use of these nanocarriers for biomedical applications holds high potential. These potential nanoparticles can be utilized for wide range of applications from diagnostics, to targeted drug delivery and even within biosensors.
The spread of the Coronavirus in 2020 has resulted in serious disruption of businesses, and has also resulted in the increased load in the healthcare and pharmaceutical sector. However, the global pandemic has created lucrative growth opportunities in the field of nanoparticle drug delivery market, as researchers are increasingly looking at methods to increase the effectiveness of the COVID-19 vaccine, along with ensuring proper delivery of medicines to the affected patients. For instance, Sinopharm in collaboration with the Wuhan Institute of Biological Products, used aluminum salts, graphene, silica nanoparticles, gold nanoparticles, liposomes, and polymerized nanoparticles as vaccine adjuvants. Moderna used lipid encapsulation for their COVID-19 vaccine development. Based on immunogenicity, several studies have demonstrated that gold nanoparticles, spike protein nanoparticles, and hollow polymeric nanoparticles could effectively induce a human response against coronavirus.
As per our report findings, the global nanoparticle drug delivery market is expected to surpass US$ 300 Billion by 2028. The major factor that contributes to the growth of nanoparticle drug delivery market include surge in awareness related to use of nanoparticle drug delivery systems. Furthermore, other factors such as rise in healthcare expenditure and surge in governmental support for research in the field of drug delivery fuel the growth of nanoparticle drug delivery market. In addition, increase in prevalence of various chronic diseases, which require the use of nanoparticle drug delivery systems is another major factor that contributes to the growth of market.
The global nanoparticle drug delivery market is highly competitive, owing to presence of prominent players in the market. These players have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market are Abbvie, Nanobiotix, Novartis, BioGen, Bristol Myers Squibb, Arrowhead Pharmaceuticals, Tandem Nano, and several others. These companies have developed a robust clinical pipeline of nanoparticle drug deliveries which will also have a positive impact on the growth of market during the forecast period.
The report Nanoparticle drug delivery market provides comprehensive analysis on the commercially available nanomedicines along with their price, dosage, generic availability, and sales analysis. Moreover, in-depth analysis on the ongoing clinical trials in the report is also included in the report. Further, key players and their strategies are thoroughly analyzed to provide competitive outlook to the industry.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com